Healthcare | May 08, 2026
Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
